Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association

American Journal of Hematology

Volumn 87, Issue 1, 2012, Pages 62-65

  Farhat, Hassan ^a   Reman, Oumedaly ^a   Raffoux, Emmanuel ^a   Berthon, Celine ^a   Pautas, Cécile ^a   Kammoun, Leila ^a   Chantepie, Sylvain ^a   Gardin, Claude ^a   Rousselot, Philippe ^a   Chevret, Sylvie ^a   Dombret, Hervé ^a   Castaigne, Sylvie ^a  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMSACRINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD33 ANTIGEN; CREATININE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CATHETER INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOGENETICS; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOXICITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; MALE; MULTICENTER STUDY; NEUTROPHIL COUNT; OPTIMAL DRUG DOSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SEPSIS; THROMBOCYTE COUNT; TREATMENT DURATION; VEIN OCCLUSION;

AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84155167470     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22201     Document Type: Article

References (16)

1. Tallman MS, DG Gilliland, Rowe JM. Drug therapy of acute myeloid leukemia. Blood 2005; 106: 1154-1163.
2. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 2010; 115: 453-474.
3. Bernstein ID. Monoclonal antibodies to the myeloid stem cells: Therapeutic implications of CMA-676 a humanized anti-CD33 antibody chalicheamicin conjugate. Leukemia 2000; 14: 474-475.
4. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005; 104: 1442-1452.
5. Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the Alfa Group. Leukemia 2007; 21: 66-71.
6. van der Velden VHJ, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197-3204.
7. ISCN (International System for Human Cytogenetic Nomenclature). Guidelines for cancer cytogenetics. Mitelman F, Supplement to an International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1991. pp 1-53.
8. Renneville A, Boissel N, Zurawski V, et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: A study from the Acute Leukemia French Association. Cancer 2009; 16: 3719-3727.
9. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649.
10. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1, 612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322-2333.
11. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: Results of the ALFA-9801 study. J Clin Oncol 2010; 28: 808-814.
12. Atallah E, Cortes J, O'Brien S, et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukaemia. Blood 2007; 110: 3547-3551.
13. Burnett AK, Hills RK, Milligan D, Kjeldsen L, et al. Identification of patients withacute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial. J Clin Oncol 2011; 29: 369-377.
14. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003; 102: 4277-4283.
15. De Angelo DJ, Stone RM, Durrant S, et al. Gemtuzumab ozogamicin (Mylotarg) in combination induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: Two age-specific phase 2 trials. Blood 2003; 102: 341a.
16. Petersdorf S, Kopecky K, Stuart RK, et al. Preliminary results of Southwest oncology group study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 2009; 114:Abstract 790.